The next two months will be hugely important for the stem cell therapy company's research projects,and its growth prospects as it works on a product to treat the deadly disease.
The Australian biotech is pinning its hopes on a positive result from its coronavirus trial - though warns the path ahead will be expensive.
The $1.8 billion stem cell therapy biotech is preparing to ramp up production of its key product should clinical trials of the drug succeed.
Biotechnology giant CSL Limited's chief scientific officer says social distancing is the best weapon Australia has to fight coronavirus until a vaccine becomes available.
The boss of biotech Mesoblast,which hopes to treat respiratory issues caused by COVID-19,has warned the virus will linger even if a vaccine is found.